RxDoctor Payments Data

Enrique Esnard, MD

Neurology · Wenatchee, WANPI 1366670143

Payments from drug & device makers

$3,609in general payments, 2019–2025

Across 30 payments — averaging $120.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Medtronic$537
  • Biogen$166
  • Eisai Inc.$125
  • Livanova USA, Inc.$104
  • Argenx US, Inc.$70
  • plus $14 from 1 others

What the payments were for

  • Travel & lodging$2,26763%
  • Food & beverage$1,34137%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,609 in reported general payments places this provider in the 75th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington

Medicare billing

Part B allowed, 2024
$111,341
Medicare patients
467
Services billed
2,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ApokynApomorphine Hcl12$260,260
AustedoDeutetrabenazine23$198,756
IngrezzaValbenazine Tosylate23$176,319
Austedo XrDeutetrabenazine18$88,469
Emgality PenGalcanezumab-Gnlm73$51,642
Nurtec OdtRimegepant Sulfate30$48,698
Aimovig AutoinjectorErenumab-Aooe54$43,836
RytaryCarbidopa/Levodopa50$37,833
Carbidopa-LevodopaCarbidopa/Levodopa790$26,608
Ajovy AutoinjectorFremanezumab-Vfrm13$9,041
Carbidopa-Levodopa ErCarbidopa/Levodopa245$8,905
MyrbetriqMirabegron21$8,225
AmantadineAmantadine Hcl94$6,839
Levetiracetam228$6,614
Entacapone41$5,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$14$287,22541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 418 neurology providers in Washington.

Other neurology in Wenatchee

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →